We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Organon (OGN - Free Report) ended the recent trading session at $9.00, demonstrating a -1.1% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.41%. Meanwhile, the Dow experienced a drop of 0.83%, and the technology-dominated Nasdaq saw an increase of 0.91%.
Shares of the pharmaceutical company have appreciated by 27.99% over the course of the past month, outperforming the Medical sector's loss of 0.74%, and the S&P 500's gain of 0.38%.
Market participants will be closely following the financial results of Organon in its upcoming release. In that report, analysts expect Organon to post earnings of $0.74 per share. This would mark a year-over-year decline of 17.78%. Simultaneously, our latest consensus estimate expects the revenue to be $1.53 billion, showing a 3.84% drop compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.78 per share and a revenue of $6.24 billion, representing changes of -8.03% and 0%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Organon is holding a Zacks Rank of #3 (Hold) right now.
Looking at valuation, Organon is presently trading at a Forward P/E ratio of 2.32. This indicates a discount in contrast to its industry's Forward P/E of 16.53.
We can also see that OGN currently has a PEG ratio of 1.8. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.87.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 186, finds itself in the bottom 25% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Organon (OGN) Stock Sinks As Market Gains: What You Should Know
Organon (OGN - Free Report) ended the recent trading session at $9.00, demonstrating a -1.1% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.41%. Meanwhile, the Dow experienced a drop of 0.83%, and the technology-dominated Nasdaq saw an increase of 0.91%.
Shares of the pharmaceutical company have appreciated by 27.99% over the course of the past month, outperforming the Medical sector's loss of 0.74%, and the S&P 500's gain of 0.38%.
Market participants will be closely following the financial results of Organon in its upcoming release. In that report, analysts expect Organon to post earnings of $0.74 per share. This would mark a year-over-year decline of 17.78%. Simultaneously, our latest consensus estimate expects the revenue to be $1.53 billion, showing a 3.84% drop compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.78 per share and a revenue of $6.24 billion, representing changes of -8.03% and 0%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Organon is holding a Zacks Rank of #3 (Hold) right now.
Looking at valuation, Organon is presently trading at a Forward P/E ratio of 2.32. This indicates a discount in contrast to its industry's Forward P/E of 16.53.
We can also see that OGN currently has a PEG ratio of 1.8. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.87.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 186, finds itself in the bottom 25% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.